Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial*

D. Thaci\(^1\) K. Eyerich\(^2\), A. Pinter\(^3\), M. Sebastian\(^4\), K. Unnebrink\(^5\), S. Rubant\(^5\), D. A. Williams\(^6\) and P. Weisenseel\(^7\)

\(^1\)Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany
\(^2\)Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany
\(^3\)Department of Dermatology, Venerology and Allergology, University Hospital Frankfurt, Frankfurt am Main, Germany
\(^4\)Gemeinschaftspraxis für Dermatologie, Mahlow, Germany
\(^5\)AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
\(^6\)AbbVie Inc., North Chicago, IL, USA
\(^7\)Dermatologikum, Hamburg, Germany

**Correspondence**
Diamant Thaci
Email: diamant.thaci@uksh.de

**Accepted for publication**
13 May 2021

**Funding sources**
AbbVie Inc. funded the research for this study and participated in the study design; study research; data collection, analysis and interpretation of data; reviewing; and approval of this publication. No honoraria or payments were made for authorship. AbbVie Inc. and the authors thank all study investigators for their contributions and the patients who participated in this study. Medical writing support, funded by AbbVie Inc., was provided by Jody Bennett of AbbVie Inc., and Sonja Mohinta, Jennifer Venzie and Janet Matsuzawa of ICON (North Wales, PA, USA).

**Conflicts of interest**
See Appendix S1 (Supporting Information).

**Data availability statement**
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual- and trial-level data (analysis datasets), as well as other information (e.g. protocols and Clinical Study Reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlabeled products and indications. These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and

---

**Summary**

Background Fumaric acid esters (FAEs; Fumaderm\(^8\)) are the most frequently prescribed first-line systemic treatment for moderate-to-severe plaque psoriasis in Germany. Risankizumab (Skyrizi\(^8\)) is a humanized IgG1 monoclonal antibody that specifically binds to the p19 subunit of interleukin 23.

**Objectives** To compare risankizumab treatment to FAEs in patients with psoriasis.

**Methods** This phase III randomized, active-controlled, open-label study with blinded assessment of efficacy was conducted in Germany. Patients were randomized (1 : 1) to subcutaneous risankizumab 150 mg (weeks 0, 4 and 16) or oral FAEs at increasing doses from 30 mg daily (week 0) up to 720 mg daily (weeks 8–24). Enrolled patients were adults naïve to and candidates for systemic therapy, with chronic moderate-to-severe plaque psoriasis. Phototherapy was not allowed within 14 days before or during the study.

**Results** Key efficacy endpoints were met at week 24 for risankizumab (n = 60) vs. FAEs (n = 60) (P < 0.001): achievement of a ≥ 90% improvement in Psoriasis Area and Severity Index (PASI; primary endpoint 83-3% vs. 10-0%), ≥ 100% improvement in PASI (50-0% vs. 5-0%), ≥ 75% improvement in PASI (98-3% vs. 33-3%), ≥ 50% improvement in PASI (100% vs. 53-3%) and a Static Physician’s Global Assessment of clear/almost clear (93-3% vs. 38-3%). The rates of gastrointestinal disorders, flushing, lymphopenia and headache were higher in the FAE group. One patient receiving risankizumab reported a serious infection (influenza, which required hospitalization). There were no malignancies, tuberculosis or opportunistic infections in either treatment arm.

**Conclusions** Risankizumab was found to be superior to FAEs, providing earlier and greater improvement in psoriasis outcomes that persisted with continued treatment, and more favourable safety results, which is consistent with the known safety profile. No new safety signals for risankizumab or FAEs were observed.

---

**What is already known about this topic?**

- Risankizumab (Skyrizi\(^8\)) is approved as treatment for patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
- Risankizumab is a humanized IgG1 monoclonal antibody that specifically binds to the p19 subunit of interleukin 23.
Psoriasis is a chronic inflammatory disease that manifests as raised, well-demarcated and scaly erythematous plaques. It is one of the most prevalent immune-mediated skin diseases, affecting approximately 2% of the world’s population.1,2 Approximately 25% of patients with psoriasis have moderate-to-severe disease, which has a considerable negative impact on their psychosocial and economic status.3,4 and 20–30% experience joint involvement.5,6 Moderate-to-severe plaque psoriasis is highly correlated with comorbidities such as obesity, diabetes, depression, metabolic syndrome, nonalcoholic liver disease and cardiovascular risk.7–10 Psoriasis is frequently associated with psoriatic arthritis and inflammatory bowel disease.

Successful management of moderate-to-severe psoriasis may require phototherapy or systemic therapy. The most frequently prescribed first-line systemic treatment for psoriasis in Germany is the oral formulation of fumaric acid esters (FAEs), Fumaderm.11 FAEs are approved in Germany for patients with moderate-to-severe plaque psoriasis and reach maximum efficacy after 24 weeks of treatment.12,13 They are also recommended by the European S3-Guideline on the systemic treatment of psoriasis vulgaris as a first-line treatment before biologic treatments are considered.14 In a 2015 controlled study of FAEs in patients with psoriasis from four European countries (including Germany), 40-3% and 22-3% of patients achieved a ≥75% (PASI 75) and ≥90% (PASI 90) improvement from baseline in Psoriasis Area and Severity Index (PASI), respectively.15 Adverse events (AEs) commonly occurring after treatment with FAEs have included gastrointestinal disorders and flushing.12

Increasingly, psoriasis is being treated with biologic agents, including tumour necrosis factor (TNF)-α inhibitors (adalimumab, etanercept, infliximab and certolizumab pegol), interleukin (IL)-12/23 inhibitors (ustekinumab), IL-17 inhibitors (IL-17A: secukinumab and ixekizumab; IL-17RA: brodalumab) and, more recently, IL-23 p19 inhibitors (risankizumab, guselkumab and tilikizumab).16–19 The most effective anti-TNF and IL-12/23 agents provide approximately 75% improvement in psoriasis for approximately 60–70% of patients, with a general risk for loss of response over time, especially with TNF inhibitors. In comparison, anti–IL-17 agents may provide better efficacy, but the requirement for monthly injections hampers their long-term use.20 Anti–IL-23 agents may offer improved efficacy over the long term and convenient dosing vs. other biologic agents.

Risankizumab (Skyrizi) is a humanized IgG1 monoclonal antibody that binds to the p19 subunit and specifically inhibits IL-23, a cytokine that plays a pivotal role in the development and maintenance of psoriatic lesions.21–23 It is approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy (USA, European Union) or phototherapy (USA) and for the treatment of plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults who have an inadequate response to conventional therapies (Japan only).24–26 It has also been shown to have superior efficacy and comparable safety to the IL-12/23 inhibitor ustekinumab, the IL-17A inhibitor secukinumab, and the TNF-α inhibitor adalimumab.26–28

This study compared the efficacy and safety of subcutaneous (SC) risankizumab with oral FAEs in adult patients in Germany who had moderate-to-severe plaque psoriasis and were naïve to systemic therapy.

Patients and methods

Study design

This phase III randomized, active-controlled, multicentre, open-label study with blinded assessment of efficacy (ClinicalTrials.gov identifier NCT03255382) was conducted at 21 sites in Germany between 22 August 2017 and 6 July 2018. Patients were randomly assigned in a 1:1 ratio to receive either risankizumab 150 mg SC at weeks 0, 4 and 16, or oral FAEs at increasing doses from 30 mg daily at week 0 up to a maximum dosage of 720 mg daily at weeks 8–24, if tolerability allowed, to achieve PASI 90 (per local label; Figure 1). Patients were randomly assigned via interactive response/web response technology using block randomization and a randomization schedule for response signals.27 The results support risankizumab treatment for patients with moderate-to-severe plaque psoriasis who are naïve to systemic treatment.

What does this study add?

- In patients with psoriasis who were naïve to systemic treatment, risankizumab treatment was superior to FAEs, providing earlier and greater improvement in psoriasis outcomes that persisted to week 24.
- Risankizumab showed more favourable safety results than FAEs and no new safety signals.
- The results support risankizumab treatment for patients with moderate-to-severe plaque psoriasis who are naïve to systemic treatment.
- Fumaric acid esters (FAEs) are the most frequently prescribed first-line systemic treatment for moderate-to-severe plaque psoriasis in Germany.

DOI 10.1111/bjd.20481
Patients

Patients eligible for enrolment into this study were aged ≥ 18 and < 80 years, had been diagnosed with chronic plaque psoriasis at least 6 months before enrolment, and were naïve to and candidates for systemic therapy. They were required to have stable, moderate-to-severe plaque psoriasis, defined as a PASI score > 10, a psoriasis-affected body surface area (BSA) of > 10% and a Dermatology Life Quality Index (DLQI) score of > 10, and have an inadequate response, intolerance or contraindication to topical psoriasis treatment. Phototherapy was not allowed 14 days before screening or during participation in the study.

Patients were excluded from the study if they had nonplaque forms of psoriasis, drug-induced psoriasis or active inflammatory diseases other than psoriasis; had received systemic therapy or photochemotherapy for psoriasis; had an active systemic infection within 2 weeks of prescreening; had an active or suspected malignancy or history of malignancy within 5 years of prescreening; or had severe gastrointestinal disease, risk factors for renal toxicity, or a contraindication to Fumaderm.

Assessments

The primary endpoint was the proportion of patients who achieved PASI 90 at week 24. Key secondary efficacy endpoints were determined at multiple patient visits and included achievement of ≥ 50% improvement in PASI from baseline (PASI 50), PASI 75 and ≥ 100% improvement in PASI from baseline (PASI 100); a Static Physician’s Global Assessment (sPGA) of 0 or 1 (clear or almost clear of psoriasis, respectively; ‘static’ refers to the patient’s disease state at the time of the assessments without comparison to disease states at baseline or at a previous visit); sPGA 0; mean percentage improvement from baseline in PASI; Palmoplantar Psoriasis Area Severity Index (PPASI) and Psoriatic Scalp Severity Index (PSSI; score ranges for PASI, PPASI and PSSI 0–72; higher scores indicate more severe disease); and Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPSI; range 0–32; higher scores indicate more severe disease). An additional analysis was performed to determine the achievement of mean absolute PASI score categories of < 1, ≤ 3 and ≤ 5. Other secondary endpoints have been reported in a separate publication. Safety was assessed by monitoring AEs, laboratory values and vital signs throughout the study.

Statistical analysis

Using a two-sided χ²-test at a 5% level of significance, the sample size of 110 patients (55 per study arm) was expected to provide 94% power, assuming response rates of the primary endpoint (PASI 90 at week 24) of 70% for risankizumab and 35% for oral FAs. These assumptions aligned with reported PASI 90 response rates for risankizumab \[n = 63/83 (76\%)\] at week 24 and oral FAs \[n = 61/273 (22\%-3\%)\] at week 16 from other trials.

Efficacy analyses were performed using the intent-to-treat population (all randomized patients). Safety analyses were performed for all randomized patients who received ≥ 1 dose of the study drug. All comparisons were done with two-sided tests, with a significance level of 0.05 for the primary endpoint. Categorical variables were analysed using the Cochran-Mantel-Haenszel test stratified by prior phototherapy exposure; continuous endpoints for PASI, PPASI, PSSI and NAPSI were analysed using ANCOVA. Missing efficacy data were imputed using nonresponder imputation (NRI) for categorical endpoints and last observation carried forward for continuous endpoints. An as-observed case (OC) analysis was used as a secondary approach in the analysis of continuous endpoints and did not impute values for missing evaluations (e.g. patients who did not have an evaluation at a scheduled visit were excluded from the OC analysis for that visit).

Results

Patient characteristics

The details of the 120 randomized patients who entered the study are shown in Figure 2. No patients in the risankizumab
group discontinued the study or the study drug, compared to 13 patients (21.7%) in the FAE group (three discontinued the study because of an AE and five discontinued the study drug because of an AE).

Baseline demographics and disease characteristics were generally similar between the risankizumab and FAE treatment arms (Table 1). The majority of patients were white men (mean age 42.3 years). Most patients (61.7%) had an above-normal body mass index (BMI; ≥ 25 kg m$^{-2}$). Disease severity was shown by a mean percentage of involved BSA of 21.2%, a mean DLQI score of 20.3, a mean PASI score of 17.9 and a sPGA at least moderate for 85.8% of patients. Mean time to diagnosis was approximately 15.6 years. PASI scores at baseline were numerically higher for the risankizumab group (mean 19.0, median 18.0) than for the FAE group (mean 16.7, median 14.7), and the proportion of overweight patients (BMI ≥ 25 kg m$^{-2}$) was higher in the risankizumab group than in the FAEs group (71.7% vs. 53.3%, respectively).

Efficacy

The primary and all-reported secondary efficacy endpoints were achieved. At week 24, significantly more patients randomized to risankizumab achieved PASI 90 compared with patients randomized to FAEs [83.3% vs. 10.0% (P < 0.001); Figure 3]. Significantly more patients in the risankizumab group also achieved PASI 50, PASI 75, PASI 100, sPGA 0/1 and sPGA 0 after 24 weeks of treatment compared with patients in the FAE group (all P < 0.001).

From weeks 8 to 24, a significantly greater proportion of patients receiving risankizumab achieved clear or almost-clear skin (PASI 100 or PASI 90) compared with patients randomized to FAEs (Figure 3). An even greater proportion of these patients achieved PASI 50 and PASI 75 from weeks 4 to 24.

Significantly more patients randomized to risankizumab achieved sPGA 0/1 starting at week 4 (P < 0.001) and sPGA 0 starting at week 8 (P = 0.048) compared with patients randomized to FAEs across 24 weeks of treatment (Figure 4).

As shown in Figure 5, the mean percentage improvement in PASI score was statistically significantly higher in the risankizumab group at each time point across 24 weeks. Across weeks 8–24, the rates of achievement of PASI < 1, ≤ 3 and ≤ 5 increased in the risankizumab group and were significantly greater compared with the FAE group. A significant improvement in PASI score was also observed in the risankizumab group compared with the FAE group at each time point, using OC analysis (Figure S1; see Supporting Information).

Results for the nail, scalp and palmoplantar psoriasis secondary efficacy endpoints show that the mean percentage improvement from baseline for the risankizumab group was significantly higher compared with the FAE group for PSSI and NAPSI scores at weeks 16 and 24 and for PPASI at week 16 and increased slightly from weeks 16 to 24 (Figure 6). Using OC analysis, improvements in PSSI and NAPSI scores also showed significant differences in the risankizumab group compared with the FAE group at weeks 16 and 24. There was no statistically significant difference in PPASI scores for the risankizumab group compared with the FAE group at either time point (Figure S2; see Supporting Information).

Safety

A total of 117 patients were included in the safety analysis (60 in the risankizumab arm and 57 in the FAE arm). The rates of AEs and discontinuations of the study drug because of AEs were lower in the risankizumab group than in the FAE group; rates for AEs related to the study drug were substantially lower in the risankizumab group (Table 2). There were no meaningful differences in the rates of serious or severe AEs between the treatment groups. No patients in the risankizumab group discontinued the study drug because of an AE vs. five patients in the FAE group who discontinued the study drug because of AEs (leukopenia, lymphopenia, upper
abdominal pain, drug eruption and flushing). A substantially greater number of patients in the FAE group experienced gastrointestinal disorders, flushing, lymphopenia and headache than in the risankizumab group. There were no deaths and no cases of malignancies, tuberculosis, opportunistic infections, major adverse cardiac events or other cardiovascular events, herpes zoster–related events or serious hypersensitivity for either treatment group in the study.

Discussion

This is the first head-to-head psoriasis trial to compare risankizumab with FAEs in patients naïve to systemic treatment. In summary, the primary endpoint of this trial (i.e. achievement of PASI 90 after 24 weeks of treatment) showed the superiority of risankizumab to FAEs. The PASI 90 endpoint, which indicates clear to almost-clear skin, has been identified as the current treatment goal for psoriasis. The secondary endpoints in this trial were also achieved at week 24, with significant differences favouring risankizumab (except for PPASI, which numerically favoured risankizumab) also seen across patient visits before week 24. These results support the superiority of risankizumab to FAEs in producing clinically meaningful improvement in the extent and severity of psoriasis over time. The rates of serious and severe AEs were low in both treatment groups.

The treatment populations in this trial were generally similar to other phase III trials of risankizumab and trials of FAEs, with similar characteristics in terms of age, sex, race, mean PSO area, BMI, PASI, DLQI, NAPSI and PSSI. A substantially greater number of patients in the FAE group experienced gastrointestinal disorders, flushing, lymphopenia and headache than in the risankizumab group. There were no deaths and no cases of malignancies, tuberculosis, opportunistic infections, major adverse cardiac events or other cardiovascular events, herpes zoster–related events or serious hypersensitivity for either treatment group in the study.

Table 1 Baseline patient demographics and disease characteristics

| Characteristic                         | RZB (n = 60) | FAEs (n = 60) | All patients (n = 120) |
|----------------------------------------|--------------|--------------|------------------------|
| Sex                                    |              |              |                        |
| Female                                 | 27 (45)      | 22 (36.7)    | 49 (40.8)              |
| Male                                   | 33 (55)      | 38 (63.3)    | 71 (59.2)              |
| Mean (SD) age (years)                  | 42.0 (13.75) | 42.5 (12.71) | 42.3 (13.18)           |
| Median (range) age (years)             | 40.5 (18.0–73.0) | 42.5 (19.0–69.0) | 41.5 (18.0–73.0)       |
| Race                                    |              |              |                        |
| White                                  | 59 (98)      | 60 (100)     | 119 (99.2)             |
| Asian                                  | 1 (1.7)      | 0            | 1 (0.8)                |
| Mean (SD) weight (kg)*                 | 88.4 (23.0)  | 85.6 (22.3)  | 87.0 (22.6)            |
| Median (range) weight (kg)*            | 85.1 (49.0–146.0) | 80.0 (48.5–165.0) | 81.2 (48.5–165.0)      |
| Mean (SD) BMI (kg m⁻²)*                | 27.7 (6.1)   | 28.4 (6.5)   |                        |
| Median (range) BMI (kg m⁻²)*           | 28.0 (18.7–53.1) | 26.5 (18.7–44.8) | 27.4 (18.7–53.1)       |
| BMI < 25 (normal)                      | 27 (28)      | 26 (45)      | 43 (36.4)              |
| BMI ≥ 30 (obese)                       | 24 (20)      | 27 (19)      | 41 (34.7)              |
| Mean (SD) time since PsO diagnosis (years) | 15.8 (12.2) | 15.5 (13.6) | 15.7 (12.9)             |
| Median (range) time since PsO diagnosis (years) | 14 (0–55) | 13 (0–61) | 13 (0–61)               |
| Mean (SD) BSA (% of PsO-affected area) | 23.5 (13.6) | 19.0 (8.9)   | 21.2 (11.7)            |
| Median (range) BSA (% of PsO-affected area) | 18.0 (11.0–78.0) | 15.0 (11.0–46.0) | 16.0 (11.0–78.0)       |
| Mean (SD) PASI (score 0–72)            | 5 (9)        | 4 (7)        | 9 (7.5)                |
| Median (range) PASI (score 0–72)⁵      | 18.0 (10–39.6) | 14.5 (10–30.2) | 16.0 (10–39.6)         |
| sPGA⁴                                 |              |              |                        |
| Mild (2)                               | 7 (12)       | 9 (15)       | 16 (13–4)              |
| Moderate (3)                           | 46 (77)      | 43 (73)      | 89 (74–8)              |
| Severe (4)                             | 7 (12)       | 7 (12)       | 14 (11–8)              |
| Mean (SD) PPASI (score 0–72)⁶          | 0.7 (1.8)    | 1.5 (3.7)    | 1.1 (2.9)              |
| Median (range) PPASI (score 0–72)⁶     | 0 (0–9)      | 0 (0–17)     | 0 (0–17)               |
| Mean (SD) PSSI (score 0–72)⁶          | 23.1 (17.6)  | 20.2 (14.8)  | 21.6 (16.3)            |
| Median (range) PSSI (score 0–72)⁶     | 16 (0–60)    | 16 (0–60)    | 16 (0–60)              |
| Mean (SD) NAPSI (score 0–32)⁷         | 30.3 (35.0)  | 22.3 (27.2)  | 26.3 (31.5)            |
| Median (range) NAPSI (score 0–32)⁷     | 14 (0–147)   | 6 (0–98)     | 10 (0–147)             |
| Mean (SD) DLQI (score 0–30)⁷          | 20.0 (5.3)   | 20.5 (6.0)   | 20.3 (5.7)             |
| Median (range) DLQI (score 0–30)⁷      | 20.0 (8–30.0) | 20.5 (7–30.0) | 20.0 (7–30.0)          |
| Prior phototherapy for PsO             | 10 (17)      | 11 (18)      | 21 (18)                |

Data are n (%) unless otherwise specified. BMI, body mass index; BSA, body surface area; DLQI, Dermatology Life Quality Index; FAEs, fumaric acid esters (oral formulation); NAPSI, Nail Assessment in Psoriasis and Psoriatic Arthritis; PSSI, Psoriasis Area Severity Index; PPASI, Psoriatic Plaque Severity Index; PASI, Psoriasis Area Severity Index; PsO, psoriasis; PSSI, Psoriatic Scalp Severity Index; RZB, risankizumab; sPGA, Static Physician’s Global Assessment. ⁴Data missing for FAEs: n = 2 for weight; BMI: n = 1 for sPGA, PPASI, PSSI and NAPSI. Data missing for RZB: n = 2 for NAPSI. ⁵BMI categories were defined in the protocol. ⁶Higher scores indicate more disability or disease severity.
disease burden, as shown by an overall mean PASI score of 17.9, a mean DLQI score of 20.3, a mean percentage of psoriasis-involved BSA of 21.2% and a mean time to disease diagnosis of 15.6 years. The higher disease burden was comparable to that of other phase III randomized, open-label, head-to-head trials of biologics and FAEs in systemic treatment–naïve patients, possibly because these patients have a greater perception of impairment to their quality of life. The current trial was conducted in Germany, whereas other phase III trials of risankizumab were conducted across multiple global regions, and some FAE trials were carried out in Europe. Compared with other risankizumab trials, the current risankizumab population was slightly younger with a higher disease burden in terms of mean DLQI score, and any prior systemic therapy in the past was not allowed.

In this trial, the rates of disease improvement – as measured by achievement of PASI 75, PASI 90 and PASI 100, and of sPGA 0/1 after 24 weeks of risankizumab treatment – are consistent with rates after 52 weeks of treatment in other phase III trials of risankizumab that evaluated moderate-to-severe plaque psoriasis, and were higher for risankizumab in the current trial than rates after 24 weeks of treatment with biologics in the other head-to-head vs. FAE trials. Treatment response was more rapid after risankizumab treatment than it was after FAE treatment, which is consistent with the other head-to-head biologics vs. FAE trials. For the FAE group in this study, rates of disease improvement, as measured by PASI 75, PASI 90 and PASI 100 at week 24, are comparable to rates in head-to-head trials with other biologics at week 24. The risankizumab group showed significantly greater mean improvement in PASI score across all six measured time-points compared with the FAE group.

Treatment response when measured using relative PASI (achievement of a 50%, 75%, 90% or 100% improvement in
PASI from baseline) can be problematic because the accuracy and relevance of the measurement depend on a baseline PASI measurement, which is not always available in the clinical setting. Thus, absolute PASI is becoming an attractive alternative for evaluating therapeutic response\textsuperscript{42–45}; however, a consensus on definitive, clinically meaningful target scores that can be associated with levels of disease improvement has not yet been reached.\textsuperscript{42,46–48}

Our analysis of absolute PASI < 1, ≤ 3 and ≤ 5 showed significantly greater achievement rates in the risankizumab group than in the FAE group, starting at week 8 (week 4 for PASI ≤ 5). These rates are consistent with rates at week 24 from a head-to-head trial of guselkumab vs. FAEs; 67% vs. 10% achieved PASI ≤ 1 and 90% vs. 24% achieved PASI ≤ 3 (NRI).\textsuperscript{29} Achievement rates for risankizumab at week 16 were comparable to rates from the phase III UltIMMA-1 and UltIMMA-2 risankizumab pooled analysis (PASI ≤ 1: 58.9%; ≤ 3: 82.9%).\textsuperscript{49} and higher than rates in other trials of biologic treatment for psoriasis, which included secukinumab [retrospective, real-world study (week 24): 45.5%, 71.2% and 77.0% achieved absolute PASI ≤ 1, ≤ 3 and ≤ 5, respectively; NRI],\textsuperscript{10} ustekinumab [phase III TRANSIT study (week 28): 37%, 66% and 83% achieved absolute PASI ≤ 1, ≤ 3 and ≤ 5, respectively; observed]\textsuperscript{43} and ixekizumab [phase III UNCOVER-2 and UNCOVER-3 pooled analysis (week 12): 54.6%, 80.8% and 89.3% achieved absolute PASI ≤ 1, ≤ 3 and ≤ 5, respectively; NRI].\textsuperscript{45}

Moderate-to-severe psoriasis manifestations in the nails, scalp and palmoplantar areas do not respond as well to therapy as skin psoriasis. This trial is the only trial of risankizumab and the only head-to-head trial of biologics vs. FAEs that evaluated scalp, palmoplantar and nail psoriasis treatment outcomes in systemic treatment-naïve patients with moderate-to-
Table 2 Summary of treatment-emergent adverse events (AEs) over 24 weeks

| Event                  | Treatment       | RZB (n = 60) | FAEs (n = 57) |
|------------------------|-----------------|--------------|---------------|
| AE                     |                 | 49 (82)      | 57 (100)      |
| SAE                    |                 | 1 (2)        | 2 (4)         |
| AE leading to discontinuation of study drug | | 0 (0) | 5 (9) |
| AE assessed as related to study drug | | 15 (25) | 52 (91) |
| SAE assessed as related to study drug | | 1 (2) | 0 (0) |
| Infections             |                 | 43 (72)      | 35 (61)       |
| Severe AE              |                 | 4 (7)        | 3 (5)         |
| AE rate of > 10% in any group | | | |
| Nasopharyngitis        |                 | 35 (58)      | 26 (46)       |
| Diarrhoea              |                 | 4 (7)        | 32 (56)       |
| Upper abdominal pain   |                 | 1 (2)        | 26 (46)       |
| Flushing               |                 | 0 (0)        | 23 (40)       |
| Headache, Abdominal pain |             | 5 (8)        | 7 (12)        |
| Nausea                 |                 | 0 (0)        | 11 (19)       |
| Lymphopenia            |                 | 0 (0)        | 8 (14)        |
| Hypersensitivity       |                 | 1 (2)        | 6 (11)        |

Treatment-emergent adverse events (AEs) were defined as any AE with an onset date on or after the first dose of study drug and up to 105 days after the last dose for risankizumab (RZB) and up to 7 days for fumaric acid esters (FAEs; oral formulation). SAE, serious adverse event. *Influenza infection and chronic obstructive pulmonary disease in one patient (RZB) requiring hospitalization. Arthralgia in one patient (FAEs) requiring hospitalization, obesity in one patient (FAEs) hospitalized for elective gastric bypass. †Leukopenia, lymphopenia, upper abdominal pain, drug eruption and flushing. ‡Investigator assessment. §MedDRA v21-0 Preferred Term.

severe psoriasis, with the exception of the guselkumab vs. FAE trial, which evaluated scalp psoriasis. Significantly greater improvements were shown in the risankizumab vs. FAE group for nail psoriasis (NAPSI) and scalp psoriasis (PSSI) at both evaluated timepoints. The risankizumab group showed numerically greater improvement in palmoplantar psoriasis (PPASI) at both timepoints. Sculp psoriasis in the guselkumab vs. FAE trial showed a greater improvement in the guselkumab group; however, improvement was measured using the scalp-specific Investigator Global Assessment and is difficult to compare with results from the PSSI used in the current study.29

In this study, the safety profiles for the risankizumab and FAE groups were consistent with the known respective safety profiles,12,13,31–33 and no new safety findings were observed. There were few serious AEs in either treatment group. No patients in the risankizumab group discontinued the study. In the FAE group, three of 13 patients who discontinued the study and five who discontinued study drug did so because of an AE; this rate (23%) was much lower than the rates in the other head-to-head trials with FAEs (60–69%).29,40,41 Five patients in the FAE group discontinued the study drug because of an AE vs. no patients in the risankizumab group. The AEs leading to discontinuation of FAEs were mostly related to gastrointestinal tolerability, lymphopenia and flushing, which is consistent with the known safety profile of FAEs.11 Serious infections in both groups (influenza and chronic obstructive pulmonary disease for one risankizumab patient, and arthralgia and obesity for one patient each in the FAE group) were considered serious because they resulted in hospitalization. The rates of overall AEs in this trial for both treatment groups were similar to the rates of biologics and FAEs in the head-to-head trials.29,40,41

The limitations of this study include a smaller number of patients vs. previous risankizumab and FAE trials, the relatively short study duration and that this study was conducted only in Germany, unlike other trials of risankizumab and FAEs that had a more global population.

The superiority of risankizumab to FAEs was consistently shown across all reported endpoints, including skin, scalp, nail and palmoplantar psoriasis. Significantly more patients randomized to risankizumab achieved clear or almost-clear skin earlier than patients randomized to FAEs. A significantly greater improvement in psoriasis from baseline was observed in the risankizumab group compared with the FAE group. The risankizumab safety profile appeared to be more favourable than that of FAEs, and was consistent with the known risankizumab safety profile. No new safety signals were observed.

Acknowledgments

The authors would like to thank the patients, study sites and investigators who participated in this clinical study and acknowledge the following contributions to this publication: Anne Caney, MD, for contributions as the study-designated physician, formerly employed by AbbVie Inc.; Monika Höbel of AbbVie Inc. for statistical programming support; and Jody Bennett of AbbVie Inc., and Sonia Mohinta, Jennifer Venzie and Janet Matsuura of ICON (North Wales, PA, USA) for medical writing support.

References

1 Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361:496–509.
2 Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445:866–73.
3 Parisi R, Symmons DP, Griffiths CE et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133:377–85.
4 Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007; 370:272–84.
5 Goff KL, Karimkhani C, Boyers LN et al. The global burden of psoriatic skin disease. Br J Dermatol 2015; 172:1665–8.
6 Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 2013; 72:736–40.
7 Mease PJ, Gladman DD, Papp KA et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with
psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 2013; 69:729–35.
8 Davidovici BB, Sattar N, Jorg PC et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010; 130:1785–96.
9 Takeshita J, Grewal S, Langan SM et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol 2017; 76:377–90.
10 Yeung H, Takeshita J, Melita NN et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol 2013; 149:1173–9.
11 De Keyser E, Busard CI, Lansens S et al. Clinical consequences of antibody formation, serum concentrations, and HLA-Cw6 status in psoriasis patients on ustekinumab. Ther Drug Monit 2019; 41:634–9.
12 Mrowietz U, Barker J, Boehncke WH et al. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. J Eur Acad Dermatol Venereol 2018; 32:3–14.
13 Mrowietz U, Altmeyer P, Bieber T et al. Treatment of psoriasis with fumaric acid esters (Fumaderm). J Dtsch Dermatol Ges 2007; 5:716–7.
14 Nast A, Gisondi P, Ormerod AD et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris – update 2015 – short version – EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2015; 29:2277–94.
15 Mrowietz U, Szepietowski JC, Loewe R et al. Etanercept as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled trial (BRIDGE). Br J Dermatol 2017; 176:615–23.
16 Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58:106–15.
17 Leonard CI, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349:2014–22.
18 Reich K, Wozel G, Zheng H et al. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE1). Br J Dermatol 2013; 168:3254–35.
19 Lebwohl M, Blauvelt A, Paul C et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol 2018; 79:266–76.
20 Leonard CI, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665–74.
21 Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675–84.
22 Langley RG, Efevski BE, Lebwohl M et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med 2014; 371:326–38.
23 Mrowietz U, Leonard CI, Girolomoni G et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPture). J Am Acad Dermatol 2015; 73:27–36.
24 Gordon KB, Blauvelt A, Papp KA et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016; 375:345–56.
25 Papp KA, Reich K, Paul C et al. A prospective phase III, randomised, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016; 175:273–86.
26 Gordon KB, Strober B, Lebwohl M et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018; 392:650–61.
27 Reich K, Gooderham M, Thaci D et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet 2019; 394:576–86.
28 Reich K, Papp KA, Blauvelt A et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (resSURFACE 1 and resSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet 2017; 390:276–88.
29 Thaci D, Pinter A, Sebastian M et al. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomised, active-comparator-controlled phase IIIb trial (POLARIS). Br J Dermatol 2020; 183:265–75.
30 Smith RL, Warren RB, Eyle S et al. Polymorphisms in the IL-12beta and IL-23R genes are associated with psoriasis of early onset in a UK cohort. J Invest Dermatol 2008; 128:1325–7.
31 SKYRIZI. Prescribing information. Available at: https://www.rxabbvie.com/pdf/skyrizi_pi.pdf (last accessed 15 June 2021).
32 Jullien D, Stauumont-Salle D. Groupe de recherche sur le psoriasis de la Société française de dermatologie. [Ustekinumab]. Ann Dermatol Venereol 2019; 146:497–502 (in French).
33 Ohtsuki M, Fujita H, Watanabe M et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustAIMM phase 2/3 trial. J Dermatol 2019; 46:868–94.
34 Warren RB, Blauvelt A, Poulin Y et al. Efficacy and safety of risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis (IMMmerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol 2021; 184:50–9.
35 Thaci D, Soliman A, Eyerich K et al. Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial. J Eur Acad Dermatol Venereol 2021. DOI: https://doi.org/10.1111/jdv.17109 (Epub ahead of print).
36 Papp KA, Blauvelt A, Bukhala M et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med 2017; 376:1551–60.
37 Strober B, Papp KA, Lebwohl M et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol 2016; 75:77–82.
38 Tonini A, Zanframundo S, Panduri S et al. Ustekinumab-induced amelioration of both palmoplantar psoriasis and psoriatic glossitis. J AAD Case Rep 2019; 5:484–7.
39 Blauvelt A, Leonard CI, Gooderham M et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol 2020; 156:649–58.
40 Sticherling M, Mrowietz U, Augustin M et al. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. Br J Dermatol 2017; 177:1024–32.

British Journal of Dermatology (2022) 186, pp30–39
© 2021 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
41 Reich K, Augustin M, Thaci D et al. A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. Br J Dermatol 2020; 182: 869–79.

42 Mahil SK, Wilson N, Dand N et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol 2020; 182: 1158–66.

43 Reich K, Puig L, Paul C et al. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis. Br J Dermatol 2014; 170: 435–44.

44 Griffiths CE, Reich K, Lebwohl M et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomized trials. Lancet 2015; 386: 541–51.

45 Puig L, Dossenbach M, Berggren L et al. Absolute and relative Psoriasis Area and Severity Indices (PASI) for comparison of the efficacy of ixekizumab to etanercept and placebo in patients with moderate-to-severe plaque psoriasis: an integrated analysis of UNCOVER-2 and UNCOVER-3 outcomes. Acta Derm Venereol 2019; 99: 971–7.

46 Zheng J. Absolute Psoriasis Area and Severity Index: an additional evaluation for clinical practice. Br J Dermatol 2017; 176: 576.

47 Carretero G, Puig L, Carrascosa JM et al. Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. J Dermatolog Treat 2018; 29: 334–46.

48 Zweegers J, Roosenboom B, van de Kerkhof PC et al. Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort. Br J Dermatol 2017; 176: 786–93.

49 Gooderham M, Pinter A, Photowala H. Durable absolute Psoriasis Area and Severity Index improvement through 52 weeks of risankizumab treatment: an integrated analysis of patients with moderate-to-severe plaque psoriasis. Presented at: 24th World Congress of Dermatology; June 10–15, 2019; Milan, Italy.

50 Chiricozzi A, Balato A, Conrad C et al. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. J Dermatolog Treat 2020; 31: 476–83.

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher’s website:

Appendix S1 Conflicts of interest.

Figure S1 Psoriasis Area and Severity Index efficacy outcomes (observed case analysis).

Figure S2 Improvement from baseline in palmoplantar psoriasis, scalp and nail outcomes (observed case analysis).